Angelina Jolie's case highlights the importance of knowing …
A group of more than 120 cancer researchers and physicians took…
Three scientists at universities in Pennsylvania, Illinois and …
Advertisement
Pfizer says Torisel-Avastin failed in cancer study
No difference in disease progression
Updated: Friday, 10 Aug 2012, 3:37 PM CDT
Published : Friday, 10 Aug 2012, 3:37 PM CDT
NEW YORK (AP) - Pfizer said Friday that its drug Torisel failed to help patients with a form of advanced kidney cancer when combined with Roche's drug Avastin.
The study compared renal cell carcinoma patients taking the Torisel-Avastin combination to those taking Avastin plus another cancer drug.
Patients taking the Pfizer combination did not show slower disease progression than those in the other group. Pfizer said.
Torisel is already approved as a stand-alone treatment for advanced renal cell carcinoma.
Opinions that are derogatory, attack other users or are offensive in nature may be removed. KXAN is not responsible for the content posted in this comment section. We reserve the right to remove any offensive or off-topic remark or thread. To mark a comment for review by a moderator, click "Report Abuse."
Email This
Print This
View Story on a Single PageAdvertisement
Advertisement
Advertisement